Impact Partnership Wealth LLC Invests $968,000 in McKesson Corporation $MCK

Impact Partnership Wealth LLC acquired a new stake in McKesson Corporation (NYSE:MCK) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,119 shares of the company’s stock, valued at approximately $968,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. SMART Wealth LLC boosted its stake in McKesson by 3.4% in the 1st quarter. SMART Wealth LLC now owns 366 shares of the company’s stock worth $317,000 after buying an additional 12 shares during the last quarter. Premier Path Wealth Partners LLC increased its stake in shares of McKesson by 18.7% during the 1st quarter. Premier Path Wealth Partners LLC now owns 754 shares of the company’s stock valued at $653,000 after acquiring an additional 119 shares during the last quarter. SJS Investment Consulting Inc. increased its stake in shares of McKesson by 7.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 172 shares of the company’s stock valued at $149,000 after acquiring an additional 12 shares during the last quarter. Moss Adams Wealth Advisors LLC lifted its holdings in shares of McKesson by 6.7% during the 1st quarter. Moss Adams Wealth Advisors LLC now owns 430 shares of the company’s stock worth $372,000 after acquiring an additional 27 shares during the period. Finally, Klein Pavlis & Peasley Financial Inc. lifted its holdings in shares of McKesson by 3.9% during the 1st quarter. Klein Pavlis & Peasley Financial Inc. now owns 1,534 shares of the company’s stock worth $1,327,000 after acquiring an additional 58 shares during the period. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: TempraMed expanded its partnership with McKesson Medical-Surgical to distribute its full portfolio across North America, adding temperature-controlled medication solutions to McKesson’s medical-surgical marketplace and potentially enhancing its healthcare provider offering. McKesson (MCK) Expands TempraMed Partnership Across North America For Full Portfolio Distribution
• Positive Sentiment: Momentum-focused commentary from Zacks characterized McKesson as a strong momentum stock, reinforcing a favorable technical and sentiment backdrop for the shares. Here’s Why McKesson (MCK) is a Strong Momentum Stock
• Positive Sentiment: Several bullish writeups highlighted McKesson’s valuation and earnings profile, suggesting some investors still view the stock as attractive despite recent volatility. Is McKesson Corporation (MCK) A Good Stock To Buy Now?
• Positive Sentiment: Another article pointed to three reasons to like McKesson, including its business quality and longer-term fundamentals, which may help support investor confidence. 3 Reasons We Love McKesson (MCK)
• Neutral Sentiment: Recent coverage also noted that McKesson had been trading lower in the prior session and remains below its recent highs, reflecting ongoing pressure from softer quarterly results and broader profit-taking. McKesson (MCK) Stock Falls Amid Market Uptick: What Investors Need to Know

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Bank of America cut their price target on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. William Blair initiated coverage on shares of McKesson in a report on Tuesday, April 28th. They issued an “outperform” rating on the stock. UBS Group boosted their price objective on shares of McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Raymond James Financial set a $970.00 price objective on McKesson in a report on Thursday, March 5th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $960.53.

McKesson Price Performance

NYSE MCK opened at $757.38 on Wednesday. McKesson Corporation has a 1-year low of $637.00 and a 1-year high of $999.00. The firm has a market capitalization of $88.67 billion, a P/E ratio of 19.69, a P/E/G ratio of 1.23 and a beta of 0.31. The business’s 50-day simple moving average is $772.99 and its 200-day simple moving average is $839.87.

McKesson (NYSE:MCK) last posted its earnings results on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The firm had revenue of $96.30 billion during the quarter, compared to the consensus estimate of $101.35 billion. During the same quarter in the prior year, the company earned $10.12 EPS. The company’s revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, equities research analysts expect that McKesson Corporation will post 44.28 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s dividend payout ratio is presently 8.53%.

Insider Buying and Selling at McKesson

In related news, EVP Thomas L. Rodgers sold 699 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $735.27, for a total transaction of $513,953.73. Following the completion of the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,667,592.36. This represents a 23.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Brian S. Tyler sold 8,463 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $775.13, for a total value of $6,559,925.19. Following the completion of the transaction, the chief executive officer directly owned 14,382 shares in the company, valued at $11,147,919.66. This trade represents a 37.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 20,285 shares of company stock worth $15,546,137 over the last three months. 0.06% of the stock is currently owned by insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.